Iovance Biotherapeutics I... (IOVA)
Iovance Biotherapeutics Statistics
Share Statistics
Iovance Biotherapeutics has 327.88M shares outstanding. The number of shares has increased by 17.17% in one year.
| Shares Outstanding | 327.88M |
| Shares Change (YoY) | 17.17% |
| Shares Change (QoQ) | 7.58% |
| Owned by Institutions (%) | 79.63% |
| Shares Floating | 265.54M |
| Failed to Deliver (FTD) Shares | 1.94K |
| FTD / Avg. Volume | 0.02% |
Short Selling Information
The latest short interest is 75.19M, so 22.93% of the outstanding shares have been sold short.
| Short Interest | 75.19M |
| Short % of Shares Out | 22.93% |
| Short % of Float | 25.16% |
| Short Ratio (days to cover) | 9.35 |
Valuation Ratios
The PE ratio is -5.76 and the forward PE ratio is -12.81. Iovance Biotherapeutics's PEG ratio is 0.18.
| PE Ratio | -5.76 |
| Forward PE | -12.81 |
| PS Ratio | 13.07 |
| Forward PS | 0.7 |
| PB Ratio | 3.02 |
| P/FCF Ratio | -5.89 |
| PEG Ratio | 0.18 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Iovance Biotherapeutics.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.74, with a Debt / Equity ratio of 0.08.
| Current Ratio | 3.74 |
| Quick Ratio | 3.31 |
| Debt / Equity | 0.08 |
| Debt / EBITDA | -0.14 |
| Debt / FCF | -0.16 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $195.79K |
| Profits Per Employee | $-444.13K |
| Employee Count | 838 |
| Asset Turnover | 0.18 |
| Inventory Turnover | 2.41 |
Taxes
| Income Tax | -2.83M |
| Effective Tax Rate | 0.75% |
Stock Price Statistics
The stock price has increased by -72.93% in the last 52 weeks. The beta is 1.04, so Iovance Biotherapeutics's price volatility has been higher than the market average.
| Beta | 1.04 |
| 52-Week Price Change | -72.93% |
| 50-Day Moving Average | 4 |
| 200-Day Moving Average | 7.67 |
| Relative Strength Index (RSI) | 43.7 |
| Average Volume (20 Days) | 9.71M |
Income Statement
In the last 12 months, Iovance Biotherapeutics had revenue of 164.07M and earned -372.18M in profits. Earnings per share was -1.28.
| Revenue | 164.07M |
| Gross Profit | 40.08M |
| Operating Income | -395.28M |
| Net Income | -372.18M |
| EBITDA | -395.28M |
| EBIT | -395.28M |
| Earnings Per Share (EPS) | -1.28 |
Balance Sheet
The company has 115.69M in cash and 57.26M in debt, giving a net cash position of 58.43M.
| Cash & Cash Equivalents | 115.69M |
| Total Debt | 57.26M |
| Net Cash | 58.43M |
| Retained Earnings | -2.38B |
| Total Assets | 910.43M |
| Working Capital | 334.68M |
Cash Flow
In the last 12 months, operating cash flow was -352.98M and capital expenditures -11.07M, giving a free cash flow of -364.05M.
| Operating Cash Flow | -352.98M |
| Capital Expenditures | -11.07M |
| Free Cash Flow | -364.05M |
| FCF Per Share | -1.26 |
Margins
Gross margin is 24.43%, with operating and profit margins of -240.92% and -226.84%.
| Gross Margin | 24.43% |
| Operating Margin | -240.92% |
| Pretax Margin | -228.56% |
| Profit Margin | -226.84% |
| EBITDA Margin | -240.92% |
| EBIT Margin | -240.92% |
| FCF Margin | -221.88% |
Dividends & Yields
IOVA does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for IOVA is $17, which is 429.6% higher than the current price. The consensus rating is "Buy".
| Price Target | $17 |
| Price Target Difference | 429.6% |
| Analyst Consensus | Buy |
| Analyst Count | 9 |
Stock Splits
The last stock split was on Sep 26, 2013. It was a backward split with a ratio of 1:100.
| Last Split Date | Sep 26, 2013 |
| Split Type | backward |
| Split Ratio | 1:100 |
Scores
| Altman Z-Score | -1.46 |
| Piotroski F-Score | 4 |